Carboplatin-Gemcitabine-Bevacizumab: Expanding Treatment Options for Recurrent Platinum Sensitive Epithelial Ovarian Cancer

Published: April 23, 2012, 7:45 p.m.

b'Carboplatin-Gemcitabine-Bevacizumab represents an additional regimen to consider for management of recurrent platinum sensitive epithelial ovarian cancer, although it raises several questions regarding the role of bevacizumab in this disease setting.'